News and Trends 19 Oct 2021
Biotech VCs Face Funding Bulge Amid Struggling Stock Markets
Despite volatile biotech stocks limiting options for exit, Sofinnova Partners’ latest €472M fund highlights ballooning European venture capital and its growing focus on early-stage biotech investments. Biotech fundraising broke records in 2020 as the Covid-19 pandemic swept the globe. This year seems set to continue biotech’s winning streak in private fundraising. One example is a […]